An anonymous reader writes from a report via Bloomberg: The Food and Drug Administration cleared the first implant in the U.S. to treat heroin and opioid painkiller addictions. The product, Probuphine, may be used to treat addicts continuously for six months with the drug buprenorphine, according to a statement from the agency on Thursday. Titan Pharmaceuticals Inc. and partner Braeburn Pharmaceuticals are the two companies behind the implant and plan to bring it to the market just as Congress passed a bill aimed at addressing the opioid crisis. Buprenorphine differs from methadone in that it doesn't require a treatment program. Doctors can prescribe the implant to patients after they take a four-hour training program. The FDA rejected the implant in 2013 because the original dose that the companies proposed was too low to provide effective treatment. The companies decided to maintain the lower dose and attempt to gain approval by restricting use to patients who already were stable on such amounts. Meanwhile, employers are struggling to find workers who can pass a pre-employment drug test.

gmp writes "The NY Times and the Wall Street Journal are reporting on a new paper, published in the science journal Cell Stem Cell, where scientists, inspired by the ability of newts and other lower organisms to regrow lost limbs, have demonstrated that adult mammalian cells can be made to regenerate by suppressing a pair of anti-cancer genes. 'Interfering with tumor suppressor genes is a dangerous game, but Dr. Pomerantz said the genes could be inhibited for just a short period by applying the right dose of drug. When the drug has dissipated, the antitumor function of the gene would be restored. Finding the right combination of genes to suppress was a critical step in the new research. One of the two tumor suppressor genes is an ancient gene, known as Rb, which is naturally inactivated in newts and fish when they start regenerating tissue. Mammals possess both the Rb gene and a backup, called the Arf gene, which will close down a cancer-prone cell if Rb fails to do so.' Is regeneration nature's default, only turned off by our evolved defenses against cancer?"